Butorphanol Tartrate Preservative Free
Brand names,
Butorphanol Tartrate Preservative Free
Analogs
Butorphanol Tartrate Preservative Free
Brand Names Mixture
Butorphanol Tartrate Preservative Free
Chemical_Formula
C21H29NO2
Butorphanol Tartrate Preservative Free
RX_link
http://www.rxlist.com/cgi/generic2/butor.htm
Butorphanol Tartrate Preservative Free
fda sheet
Butorphanol Tartrate Preservative Free
msds (material safety sheet)
Butorphanol Tartrate Preservative Free
Synthesis Reference
No information avaliable
Butorphanol Tartrate Preservative Free
Molecular Weight
327.461 g/mol
Butorphanol Tartrate Preservative Free
Melting Point
No information avaliable
Butorphanol Tartrate Preservative Free
H2O Solubility
Moderate
Butorphanol Tartrate Preservative Free
State
Solid
Butorphanol Tartrate Preservative Free
LogP
4.176
Butorphanol Tartrate Preservative Free
Dosage Forms
Drops; Drug premix; Gel; Globules; Liquid; Powder for solution; Solution; Spray; Tablet
Butorphanol Tartrate Preservative Free
Indication
For the management of pain when the use of an opioid analgesic is appropriate. Also indicated as a preoperative or preanesthetic medication, as a supplement to balanced anesthesia, and for the relief of pain during labor.
Butorphanol Tartrate Preservative Free
Pharmacology
Butorphanol is a synthetic opioid agonist-antagonist analgesic with a pharmacological and therapeutic profile that has been well established since its launch as a parenteral formulation in 1978. The introduction of a transnasal formulation of butorphanol represents a new and noninvasive presentation of an analgesic for moderate to severe pain. This route of administration bypasses the gastrointestinal tract, and this is an advantage for a drug such as butorphanol that undergoes significant first-pass metabolism after oral administration. The onset of action and systemic bioavailability of butorphanol following transnasal delivery are similar to those after parenteral administration. Butorphanol blocks pain impulses at specific sites in the brain and spinal cord.
Butorphanol Tartrate Preservative Free
Absorption
Rapidly absorbed after intramuscular injection and peak plasma levels are reached in 20-40 minutes. The absolute bioavailability is 60-70% and is unchanged in patients with allergic rhinitis. In patients using a nasal vasoconstrictor (oxymetazoline) the fraction of the dose absorbed was unchanged, but the rate of absorption was slowed. Oral bioavailability is only 5-17% because of extensive first-pass metabolism.
Butorphanol Tartrate Preservative Free
side effects and Toxicity
The clinical manifestations of butorphanol overdose are those of opioid drugs in general. The most serious symptoms are hypoventilation, cardiovascular insufficiency, coma, and death.
Butorphanol Tartrate Preservative Free
Patient Information
Butorphanol Tartrate Preservative Free
Organisms Affected
Humans and other mammals